Clinical results of the blue-light filtering AcrySof Natural foldable acrylic intraocular lens
Authors:
- John MarshallJMJohn Marshall
- Robert J. CionniRCRobert J. Cionni
- James DavisonJDJames Davison
- Paul ErnestPEPaul Ernest
- Robert LehmannRLRobert Lehmann
- Andrew W. MaxwellAMAndrew W. Maxwell
- Kerry SolomonKSKerry Solomon
- 1 December 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 31 (12) , 2319-2323
Abstract
To verify the safety and effectiveness of the new AcrySof Natural (Alcon Laboratories, Inc.) blue-light filtering intraocular lens (IOL), which was designed to achieve a light-transmission spectrum similar to that of the natural human crystalline lens. Multicenter U.S. clinical trial. In a prospective randomized patient-masked multicenter study, 150 patients received the AcrySof Natural IOL and 147 patients received the AcrySof single-piece IOL as a control. Patients with bilateral age-related cataracts who were willing and able to wait at least 30 days between cataract procedures and had verified normal preoperative color vision were eligible for the study. Standardized surgery included a 4.0 to 5.0 mm capsulorhexis and phacoemulsification. All lenses were inserted in the capsular bag, with verification of in-the-bag placement of both haptics. In all bilateral implantation cases, the same model IOL was used in each eye. Postoperatively, contrast sensitivity and color perception were measured up to 180 days and up to 1 year (for visual acuity) after implantation. No statistically significant differences were discovered between the 2 patient groups in visual acuity, contrast sensitivity evaluated under mesopic and photopic conditions, or the number of patients who passed the Farnsworth D-15 color perception test. There were no lens-related adverse events in either group. The blue-light filtering AcrySof Natural IOL was equivalent to the conventional AcrySof lens in terms of postoperative visual performance. Additional long-term clinical studies should show whether the IOL actually provides the theoretical benefits to retinal health.Keywords
This publication has 11 references indexed in Scilit:
- Quality-of-life improvements in cataract patients with bilateral blue light–filtering intraocular lenses: Clinical trialJournal of Cataract & Refractive Surgery, 2005
- Evaluation of neodymium:yttrium-aluminum-garnet capsulotomies in eyes implanted with AcrySof intraocular lenses 1 1The authors have no financial or proprietary interest in any products mentioned in this paper.Ophthalmology, 2002
- Comparison of AcrySof MA30BA and Sensar AR40 acrylic intraocular lensesJournal of Cataract & Refractive Surgery, 2002
- Preliminary results of cataract extraction with implantation of a single-piece AcrySof intraocular lensJournal of Cataract & Refractive Surgery, 2002
- Eradication of posterior capsule opacificationOphthalmology, 2001
- Adhesion of fibronectin, vitronectin, laminin, and collagen type IV to intraocular lens materials in pseudophakic human autopsy eyesJournal of Cataract & Refractive Surgery, 2000
- Lens epithelial cell regression on the posterior capsule with different intraocular lens materialsBritish Journal of Ophthalmology, 1998
- Relationship between intraocular lens biomaterials and posterior capsule opacificationJournal of Cataract & Refractive Surgery, 1998
- Sandwich theory: Bioactivity-based explanation for posterior capsule opacificationJournal of Cataract & Refractive Surgery, 1997
- Spectroscopic Evaluation and Classification of the Normal, Aging, and Cataractous Lens. (With 1 color plate)Ophthalmic Research, 1976